Published on 12/15/2005 in the Prospect News Biotech Daily.
New Issue: Oxigene raises $23.7 million in upsized follow-on at $3.65, discounted from $4.30 close
By Ronda Fears
Nashville, Dec. 15 - Oxigene, Inc. priced an upsized follow-on offering of 6.5 million shares of common stock at $3.65 per share, discounted from Wednesday's closing level of $4.30, via bookrunner SG Cowen & Co. LLC.
The off-the-shelf deal for $23.725 million in proceeds was boosted from 6 million shares.
Waltham, Mass.-based Oxigene is engaged in research and development of products to treat cancer and certain eye diseases.
Issuer: | Oxigene Inc.
|
Issue: | Follow-on stock offering
|
Proceeds: | $23.725 million
|
Shares: | 6.5 million shares, up from 6 million
|
Greenshoe: | 900,000 shares
|
Price: | $3.65 per share
|
Bookrunner: | SG Cowen & Co. LLC
|
Co-manager: | Lazard Capital Markets LLC
|
Pricing date: | Dec. 15
|
Settlement date: | Dec. 20
|
Ticker: | OXGN
|
Stock price: | $4.30 at close Dec. 14
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.